Concord Biotech Limited (CONCORDBIO) — Financial Flexibility Index
Concord Biotech Limited (CONCORDBIO) has a Financial Flexibility Index of 1.62x as of March 2025. Free cash flow of Rs3.59 Billion (operating CF Rs2.47 Billion minus capex Rs1.11 Billion) represents 2% of total liabilities (Rs2.22 Billion). Check CONCORDBIO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Concord Biotech Limited Financial Flexibility Index (2020–2025)
Historical Financial Flexibility Index trend for Concord Biotech Limited across 6 annual periods. See CONCORDBIO current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Concord Biotech Limited (2020–2025)
Year-by-year free cash flow to debt coverage for Concord Biotech Limited. For the full company profile including market capitalisation, see CONCORDBIO market cap.
| Year | Flexibility Index | Free Cash Flow (INR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.62x | Rs3.59 Billion | Rs2.47 Billion | Rs2.22 Billion | ▼ -19.8% |
| 2024 | 2.02x | Rs3.51 Billion | Rs2.65 Billion | Rs1.74 Billion | ▲ +15.5% |
| 2023 | 1.75x | Rs3.91 Billion | Rs2.46 Billion | Rs2.24 Billion | ▲ +0.8% |
| 2022 | 1.73x | Rs3.63 Billion | Rs2.07 Billion | Rs2.10 Billion | ▼ -14.5% |
| 2021 | 2.03x | Rs3.71 Billion | Rs1.67 Billion | Rs1.83 Billion | ▲ +11.1% |
| 2020 | 1.82x | Rs3.10 Billion | Rs1.55 Billion | Rs1.70 Billion | — |